COMPANY

Venturis Therapeutics

Keywords: coronary artery disease peripheral artery disease neurology impotence Peripheral Arterial Disease Stenosis Intermittent Claudication Chronic Wounds Diabetes Venous Stasis Ulcers Coronary Disease Coronary Heart Disease Myocardial Ischemia Coronary Arteriosclerosis FGF-1

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

Oct 15, 2028 Trial start Phase 1/Phase 2: FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease source ↗
Sep 1, 2027 Trial start Phase 2: Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease source ↗
Sep 2, 2005 Trial start Phase 1: FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers source ↗

Upcoming milestones

Nov 15, 2029 (ESTIMATED) · Phase 2 · Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease · NCT00117936
Feb 5, 2030 (ESTIMATED) · Phase 1/Phase 2 · FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease · NCT00424866

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT00424866	FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease	Phase 1/Phase 2	Not yet recruiting	Oct 15, 2028	Feb 5, 2030 (estimated)
NCT00425178	FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers	Phase 1	Completed	Sep 2, 2005	Sep 2, 2006 (actual)
NCT00117936	Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease	Phase 2	Not yet recruiting	Sep 1, 2027	Nov 15, 2029 (estimated)